Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
It is involved in many of the processes of our cells, including the levels of free radicals that are produced
In the case of aging, it is known that over time, mitochondrial dysfunction occurs in parallel with NAD + depletion in muscle tissues, and often this depletion has been linked to muscle wasting or loss of muscle function 240,241
Sugar FREE
GHRP-6 is not a substitute for injectable HGH and should not be expected to match it
How Serena Williams admission of using a GLP-1 drug could impact the stigma of obesity Serena Williams GLP-1 disclosure may shift obesity conversations, though treatment requires a holistic approach, Northeastern experts say
